Accera Posts Phase III Alzheimer's Failure, But Moves Ahead With New Formulation
Accera blamed the study's failure on a revised formulation for AC-1204, but the company plans to begin a second Phase III trial with an improved formulation of the drug in the second or third quarter of 2017.
You may also be interested in...
US VC investment in biopharma totaled $14.5bn in the first three quarters of 2018, exceeding the full-year 2017 sum of $11.9bn. UK biotech cash also is rising, benefitting new companies like Sitryx.
E-Scape's Series A cash will fund the development of small molecules targeting genetic drivers of neurodegenerative diseases, such as ApoE4 in Alzheimer's disease. The venture capital financing with big pharma backing will be used to take two programs into the clinic.
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.